The U.S. Food and Drug Administration declined to approve Uniycive Therapeutics' NASDAQ:UNCY drug to treat elevated phosphate levels in chronic kidney disease patients on dialysis, the company said on Tuesday.
Reuters
US FDA declines to approve Unicycive's drug for dialysis patients
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- NASDAQ:UNCY
- Language
- English